July 18 (Reuters) - Boiron SA BOIR.PA :
* THE DEVELOPMENT OF THE GROUP'S SALES OVER 2023 WILL DEPEND
ON
THE CONTINUATION OF THE CURRENT MOMENTUM IN HOMEOPATHIC
SPECIALTIES, FUTURE LAUNCHES AND THE LEVEL OF PATHOLOGY AT THE
END OF THE YEAR.
* Q2 REVENUE EUR 107.6 MILLION VERSUS EUR 110.9 MILLION YEAR
AGO
* EVOLUTION OF THE GROUP'S SALES IN 2023 WILL DEPEND ON THE
CONTINUATION OF THE CURRENT MOMENTUM IN HOMEOPATHIC SPECIALTIES,
FUTURE LAUNCHES AND THE LEVEL OF PATHOLOGIES AT THE END OF THE
YEAR
Source text for Eikon: ID:nACT81033
Further company coverage: BOIR.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))